These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 19738136

  • 1. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.
    Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD.
    Circulation; 2009 Sep 22; 120(12):1029-35, 2 p following 1035. PubMed ID: 19738136
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.
    Whitlock RP, Fordyce CB, Midei MG, Ellis D, Garcia D, Weitz JI, Canafax DM, Albrecht D, Milner PG.
    Thromb Haemost; 2016 Aug 01; 116(2):241-50. PubMed ID: 27173100
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.
    Patrick AR, Avorn J, Choudhry NK.
    Circ Cardiovasc Qual Outcomes; 2009 Sep 01; 2(5):429-36. PubMed ID: 20031873
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. High intra- and inter-individual variability of plasma vitamin K concentrations in patients with atrial fibrillation under warfarin therapy.
    Kim YE, Woo HI, On YK, Kim JS, Lee SY.
    Eur J Clin Nutr; 2015 Jun 01; 69(6):703-6. PubMed ID: 25828628
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Genetic help for a blood-thinner balancing act? There's little evidence yet that a genetic test improves the safety of warfarin.
    Harv Heart Lett; 2007 Dec 01; 18(4):1-2. PubMed ID: 18219801
    [No Abstract] [Full Text] [Related]

  • 13. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand.
    Kuanprasert S, Dettrairat S, Palacajornsuk P, Kunachiwa W, Phrommintikul A.
    J Med Assoc Thai; 2009 Dec 01; 92(12):1597-601. PubMed ID: 20043560
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
    Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, Halkin H, Almog S.
    Clin Pharmacol Ther; 2005 May 01; 77(5):365-72. PubMed ID: 15900282
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Warfarin resistance.
    Sinxadi P, Blockman M.
    Cardiovasc J Afr; 2008 May 01; 19(4):215-7. PubMed ID: 18776969
    [Abstract] [Full Text] [Related]

  • 19. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL.
    Thromb Haemost; 2008 Aug 01; 100(2):229-39. PubMed ID: 18690342
    [Abstract] [Full Text] [Related]

  • 20. [Anticoagulation with warfarin].
    Schinzel H, Nitschmann S.
    Internist (Berl); 2009 Aug 01; 50(8):1026-8. PubMed ID: 19499193
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.